Over the past 20 years, medicinal nicotine has been used to aid smoking cessation, and has led to a significant increase in the number of smokers who successfully quit. This review describes currently available medicinal nicotine products, which include nicotine patch, gum, lozenge, nasal spray, inhaler and sublingual tablet, including their pharmacokinetics and recommended dosing. New developments in nicotine delivery that could further increase cessation rates include high-dose patches, rapid release gum, combined patch and acute forms, and several novel channels for nicotine delivery, such as nicotine drink, straw, lollipop and a pulmonary inhaler. New applications of existing and novel medicinal nicotine products may include relapse prevention, nicotine maintenance, temporary withdrawal management, reduced smoking and gradual quitting.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1517/17425247.2.3.563 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Examining Electronic Nicotine Delivery System (ENDS) Cue Reactivity Using a Remote Platform: Cigarette and ENDS Desire in Dual Users.
Nicotine Tob Res
January 2025
University of Chicago, Department of Psychiatry and Behavioral Neuroscience, Chicago, IL.
Introduction: Prior research shows that in-person exposure to electronic nicotine delivery systems (ENDS) use increases desire for cigarettes and ENDS. However, less is known about the impact of cues delivered during remote interactions. This study extends previous in-person cue work by leveraging a remote confederate-delivered cue-delivery paradigm to evaluate the impact of dual nicotine vaping (vs.
View Article and Find Full Text PDFPrevalence of Popular Smoking Cessation Aids in England and Associations With Quit Success.
JAMA Netw Open
January 2025
Department of Behavioural Science and Health, University College London, London, United Kingdom.
Importance: A wide range of medications, noncombustible nicotine products, behavioral support, and alternative treatments are available in England to help people stop smoking. Understanding their effectiveness outside of clinical trial settings can support informed decision-making.
Objectives: To provide up-to-date estimates of the prevalence of different smoking cessation aids and associations with quit success and to explore moderation by socioeconomic position.
Co-occurring Change in Electronic Nicotine Delivery System (ENDS) and Cigarette Harm Perceptions and Use in Young Adults.
Nicotine Tob Res
January 2025
Southwest Interdisciplinary Research Center, School of Social Work, Arizona State University, Phoenix, AZ, USA.
Introduction: Use of electronic nicotine delivery systems (ENDS) may contribute to cigarette use and nicotine addiction by shifting perceptions and norms around tobacco, but little is known about whether or how ENDS use and norms are related to cigarette use and norms, particularly among young adults. This study tested two potential mechanisms by which END use may facilitate cigarette use: decreasing tobacco harm perceptions (desensitization) and increasing favorability of tobacco use (renormalization).
Method: Analyses included data from 2187 young adults in a longitudinal panel who reported any ENDS or combustible cigarette use at ages 21, 23, or 26.
Multi-Omics Assessment of Puff Volume-Mediated Salivary Biomarkers of Metal Exposure and Oxidative Injury Associated with Electronic Nicotine Delivery Systems.
Environ Health Perspect
January 2025
Chemical Insights Research Institute, UL Research Institutes, Marietta, Georgia, USA.
Background: Since their inception, electronic nicotine delivery systems (ENDS) have gained increasing popularity, sparking a vaping epidemic among adolescents in the US and globally. Several ENDS safety concerns have emerged as device features and formats that contribute to heavy metal exposure and toxicity continue to evolve and outpace regulatory efforts.
Objectives: Our objective was to integrate ENDS emission profiles with salivary proteome and metabolome data to characterize exposure factors that may influence adverse vaping-mediated health outcomes.
Use of nicotine vaping products during an attempt to quit smoking by Canadian adults who smoke or recently quit: findings from the 2022 Canada International Tobacco Control Four Country Smoking and Vaping Survey.
Health Promot Chronic Dis Prev Can
January 2025
Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA.
An analysis of 1771 Canadian adults who smoke or used to smoke cigarettes was conducted using data from the 2022 International Tobacco Control Four Country Smoking and Vaping Survey. Using weighted data, we estimated the prevalence of Canadian adults who tried to quit smoking between 2020 and 2022, and the use of a nicotine vaping product (NVP) and the flavours and devices used most often at their most recent quit attempt. Overall, 36.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!